

Bronchopulmonary Dysplasia

1

**TERRENCE SHENFIELD MS, RRT-
ACCS, NPS, RPFT, AE-C**



Bronchopulmonary Dysplasia

2

- Definition
- Incidence
- Pathogenesis
- Pathophysiology
- Respiratory management
- Future therapies



Definition

3

- Classic BPD as described by Northway in 1967
- “New” BPD

Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline membrane disease. N Engl J Med 1967;276:357.



Classic BPD

4


- First described by Northway in 1967
- He noticed the chronic lung changes the babies who survived mechanical ventilation for treatment of RDS
- Divided into four stages
 - Stages 1 and 2 occur in 1st ten days of life and are indistinguishable from RDS
 - Stages 3 and 4 transition into chronic stages of lung disease
- Required component:
 - Respiratory support beyond one month of age
 - Ventilation or oxygen therapy



Chest X-ray

5

- Cyst formation
- Interstitial thickening
- Fibrotic changes
- Hyperexpansion
- Alternating areas of atelectasis



New BPD


6

- Eduardo Bancalari MD further refined the definition to include
- Ventilation for the first three days of life
- Respiratory symptoms at 28 days of life
 - Tachypnea
 - Auscultatory rales
 - Retractions
- Need for supplemental oxygen to maintain a partial pressure of oxygen at 50 mmHg
- Most important definition is the need for supplemental oxygen at 28 days of life and appropriate radiographic findings



BPD X-ray

7



Incidence


8

- Depends on birth weight and is inversely related
- <1000 g: 40-85%
- 1000-1500 g: 10-30%
- >1500 g: 3-5%



Pathogenesis

9



Pathogenesis

10


- At 26 weeks saccules function as “alveoli”
- Vascular proliferation finishes at 26 weeks
- Alveolar hypoplasia
- Alveoli appear around 30 weeks
- Fetal lung must continue to develop



Pathogenesis

11

PATHOGENESIS OF BPD



No single factor has been identified as the cause of BPD

12

- Barotrauma/Volutrauma
- Oxygen/antioxidants
- Inflammation
- Infection
- Nutrition
- Genetics



Barotrauma/Volutrauma

13

- Positive pressure ventilation provokes complex inflammatory cascade
- Cytokine release
- Surfactant deficiency
 - Increased surface tension
- Pulmonary interstitial emphysema (PIE)/Pneumothorax
- Strongly associated with the development of BPD



Oxygen/antioxidants

14

- Balance between oxygen free radicals and antioxidant defense
- Free radicals are toxic to living cells
- During oxidative metabolism free radicals are formed
- Hypoxia and inflammation increases free radical formation



Oxygen/antioxidants


15

- Inadequate concentrations of antioxidants at birth
- Damage caused by free radicals include
 - lipid peroxidation
 - mitochondria injury
 - protein nitration
 - unraveling of nucleic acids
- Chronic hyperoxia induces inflammation and lung injury
- Epithelial and endothelial cells extremely susceptible to oxidant injury leading to edema and cell dysfunction



Antioxidants versus GA

16



Free radicals

17

Radical	Symbol	Antioxidant
Superoxide anion	O_2^-	Superoxide dismutase, uric acid, vitamin E
Singlet oxygen	1O_2	β -carotene, uric acid, vitamin E
Hydrogen peroxide	H_2O_2	Catalase, glutathione peroxidase, glutathione
Hydroxyl radical	OH^\bullet	Vitamins C and E
Peroxide radical	LOO^\bullet	Vitamins C and E
Hydroperoxyl radical	$LOOH$	Glutathione transferase, glutathione peroxidase

Reference : Avery's Neonatology



The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity, a randomized, controlled trial.

Pediatrics 2000;105:295

- Multicenter trial in 2000 published in Pediatrics
- Study question- ‘Determine if high FIO₂ would prevent the development of severe ROP”
- Results-
 - Minimal effect on eyes
 - 55% increase of BPD and pulmonary infections



Inflammation

19

- Inflammation is central to the pathogenesis of BPD
- Causes-
 - ✦ Oxygen free radicals
 - ✦ Pulmonary barotrauma
 - ✦ Infectious agents
- Mechanism
 - ✦ Activation of leukocytes and neutrophils to site of injury
- Inflammatory mediators
 - ✦ Cytokines
 - ✦ Tumor necrosis factor-alpha
 - ✦ Interleukin1-beta
 - ✦ Interleukin 8
 - ✦ Transforming growth factor- beta



Infection

20

- Studies show that infection leads to inflammation
- Types of common infection
 - Intrauterine infection
 - Chorioamnionitis
 - Funisitis
- Strong correlation between the presence of BPD and the development of late-onset sepsis
- Severity of BPD increased LOS and mortality



Nutrition

21

- Adequate calories and essential nutrients for growth may be lacking
- Immunologic and antioxidant defenses may be inadequate due to poor nutrition
- Increased metabolic needs and rapid growth requirements
- Antioxidant enzymes (e.g., copper, zinc, selenium)
- Vitamin deficiency- vitamin E and C



- Multicenter trial of vitamin A supplementation in premature infants at risk for developing BPD
- Demonstrated that large doses of intramuscular vitamin A three times per week
 - 7% reduction in the incidence of BPD
- Findings- Vitamin A deficiency is an important contributor to lung injury.



Genetics

23

- Strong family history for asthma
- Family history of airway hyperactivity
- Genetic research for BPD will potentially pave the way to improved preventive and therapeutic approaches



Respiratory Management

24

- Mechanical Ventilation
- Oxygen
- High frequency ventilation
- Continuous positive airway pressure
- Permissive hypercapnea
- Inhaled nitric oxide
- Bronchodilators
- Corticosteroids



Mechanical Ventilation

25

- Prolonged ventilatory support
- Early Phase
 - Short inspiratory times .24-.4 seconds
 - Rapid rates 40-60
 - Low PIP 14-20 cmH₂O
 - PEEP 4-6
 - VT- 3-6 mL/kg
 - FIO₂@ < 50%
 - Blood gases
 - ✦ PaO₂ 40-60 mmHg
 - ✦ PaCO₂ 45-55 mmHg



Mechanical Ventilation

26

- Mean airway pressure maximized to reduce atelectasis
- Adequate humidity and temperature of 36.5 – 37.0
- Methylxanthines before extubation or NCPAP just after extubation may facilitate successful extubation
- HFOV as rescue if conventional ventilation fails
- Permissive hypercapnea (pH 7.28-7.35)



Oxygen

27

- Chronic hypoxia
- Vasoconstriction
- Pulmonary hypertension
- Oxygen is a pulmonary vasodilator- stimulating the production of endogenous NO
- PaO₂ should be maintained between 50 and 70 mm Hg in infants with BPD
- Maintain oxygen saturations at 88% to 92%
- If oxygen-dependent infants can maintain an SaO₂ of more than or equal to 90% for at least 40 minutes in room air they can be successfully weaned from supplemental oxygen



HFOV

28

- Henderson-Smart DJ, Bhuta T, Cools F, et al. “Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants” Cochrane Database System Rev; 2003: CD000104
- Meta-analysis
- Randomized 1771 preterm or low birth weight infants with respiratory failure to HFOV versus conventional ventilation
- Reduction in BPD at 36 weeks postmenstrual age (PMA) of borderline significance (random effects model RR = 0.70; 95% CI = 0.46-1.06)



HFOV

29

- Courtney SE, Durand DJ, Asselin JM, et al. “High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants” N Engl J Med 2002; 347:643-652
- Randomized clinical trial
- 500 infants born at 601-1200g
- HFOV versus conventional ventilation before 4 hours of age
- Reduced the need for supplemental oxygen need at 36 weeks PMA from 56% to 47%



CPAP

30

- Avery ME, Tooley WH, Keller JB, et al.” Is chronic lung disease in low birth weight infants preventable? A survey of eight centers” Pediatrics 1987; 79:26-30
- First to consider the possibility that the use of CPAP, a gentler less invasive form of respiratory support, might reduce pulmonary injury and subsequent BPD
- After controlling for known confounding factors, the NICU with the highest use of CPAP had the lowest rate of BPD
- Evidence-based approach is lacking



Continuous Positive Airway pressure

31

- Narendran V, et al.” Early bubble CPAP and outcomes in ELBW preterm infants' Perinatol 2003; 23:195-199
- Observational study of 171 infants born at 401-1000g
- Bubble CPAP used as the initial mode
- 10% trend toward improvement in the composite outcome of death or oxygen requirement at 36 weeks PMA



CPAP

32

- Thomson MA, Yoder BA, Winter VT, et al. "Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure" Am J Respir Crit Care Med 2004; 169:1054-1062
- CPAP was used in an extremely preterm baboon model of BPD
- 125 days gestation (term baboon gestation is 185 days)



Thomson et al.

33

- Preterm baboon infants were given two doses of surfactant, daily caffeine, and were extubated to CPAP at 24 hours of age versus conventional ventilation
- Evaluations at 28 days of the CPAP-treated animals showed
 - minimal evidence of pulmonary injury
 - minimal fibrosis or inflammation
 - pulmonary compliance similar to 156-day full term baboon infants



Permissive hypercapnea

34

- Provide adequate oxygenation and ventilation without associated lung injury
- “Gentle ventilation”
- Minimize barotrauma and volutrauma
- New data from the lamb model of BPD suggest that the benefits of permissive hypercapnea might extend beyond the reduction in pressure-induced pulmonary injury



Permissive hypercapnea

35

- Strand M, Ikegami M, Jobe AH.
- Effects of high PCO₂ on ventilated preterm lamb lungs.
- *Pediatr Res* 2003; 53:468-472



Strand et al.

36

- Preterm lambs subjected to identical peak inspiratory pressures, tidal volumes, and inspired oxygen
- Supplemental exogenous carbon dioxide to reach targeted PaCO₂ levels ~100 mm Hg (control PaCO₂s ~40-50 mm Hg)
- Results.....
- Decreased pulmonary inflammation
 - Decreased WBC
 - Decreased hydrogen peroxide (free radical)
 - Decreased IL-1 and ,IL-8 (inflammatory cytokines)
- Suggesting a beneficial effect of higher PaCO₂ independent of minimal ventilation-related reduction in barotrauma



Permissive hypercapnea

37

- Carlo WA, Stark AR, Wright LL, et al. “Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants” J Pediatr 2002; 141:370-374
- Randomized factorial design trial
- Primary outcome of death or BPD at 36 weeks PMA
- 220 infants



Carlo et al.

38

- 501-1000g requiring MV < 12 hours of age for a total of 10 days
- Used conventional ventilation
- FIO₂ ≥ .30 and dexamethasone
- (PaCO₂ <48 mm Hg) OR (PaCO₂ >52 mm Hg)
- Relative risk for death or BPD at 36 weeks PMA was 0.93 (95% CI = 0.77-1.12)
- Ventilator support was significantly reduced at 36 weeks in the hypercapnea group (1% vs 16%; P < 0.01)



Inhaled nitric oxide

39

- Schreiber MD, Gin-Mestan K, Marks JD, et al. “Inhaled nitric oxide in premature infants with the respiratory distress syndrome “ . N Engl J Med 2003; 349:2099-2107
- Randomized clinical trial of 207 infants
- Significant reduction in the composite outcome of death or BPD at 36 weeks PMA
- iNO treated (49% vs 64%).



Schreiber et al.

40

- Magnitude of this effect was greater among infants whose respiratory illness was less severe (oxygenation index <6.94)
- Mortality rates among control subjects in the study population were higher than have been observed at some centers, raising questions regarding whether the study results are generalizable to broader populations
- Take a prudent approach to iNO therapy among preterm infants



Bronchodilators

41

- β 2-agonist is the agent of choice in the treatment of reversible bronchospasm in infants with BPD
- Ipratropium bromide is a related muscarinic antagonist
- Methylxanthines (e.g., caffeine, theophylline)



Corticosteroids

42

- Potent anti-inflammatory properties
- Dexamethasone
- Down-regulation of the inflammatory cascade
- Improvements in pulmonary function in infants with severe BPD
- Excessive doses and prolonged use of corticosteroids result in...
 - Impair head growth
 - Neurodevelopmental outcome
 - Poor lung structure
 - Decreased long-term survival



Summary

43

- BPD is here to stay
- Gentle ventilation
- CPAP
- Prenatal care



References

- Jobe, A. H., & Bancalari, E. (2001). Bronchopulmonary dysplasia. *American journal of respiratory and critical care medicine*, 163(7), 1723-1729.
- Carraro, S., Filippone, M., Da Dalt, L., Ferraro, V., Maretti, M., Bressan, S., ... & Baraldi, E. (2013). Bronchopulmonary dysplasia: the earliest and perhaps the longest lasting obstructive lung disease in humans. *Early human development*, 89, S3-S5.
- Gadhia, M. M., Cutter, G. R., Abman, S. H., & Kinsella, J. P. (2014). Effects of Early Inhaled Nitric Oxide Therapy and Vitamin A Supplementation on the Risk for Bronchopulmonary Dysplasia in Premature Newborns with Respiratory Failure. *The Journal of pediatrics*, 164(4), 744-748.
- Mehta, P., Berger, J., Bucholz, E., & Bhandari, V. (2014). Factors affecting nasal intermittent positive pressure ventilation failure and impact on bronchopulmonary dysplasia in neonates. *Journal of Perinatology*.

